A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Explainable discovery of disease biomarkers: The case of ovarian cancer to illustrate the best practice in machine learning and Shapley analysis




TekijätHuang Weitong, Suominen Hanna, Liu Tommy, Rice Gregory, Salomon Carlos, Barnard Amanda S

KustantajaElsevier

Julkaisuvuosi2023

JournalJournal of Biomedical Informatics

Tietokannassa oleva lehden nimiJournal of biomedical informatics

Lehden akronyymiJ Biomed Inform

Artikkelin numero104365

Vuosikerta141

ISSN1532-0464

eISSN1532-0480

DOIhttps://doi.org/10.1016/j.jbi.2023.104365

Verkko-osoitehttps://doi.org/10.1016/j.jbi.2023.104365

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179594009


Tiivistelmä

Objective:

Ovarian cancer is a significant health issue with lasting impacts on the community. Despite recent advances in surgical, chemotherapeutic and radiotherapeutic interventions, they have had only marginal impacts due to an inability to identify biomarkers at an early stage. Biomarker discovery is challenging, yet essential for improving drug discovery and clinical care. Machine learning (ML) techniques are invaluable for recognising complex patterns in biomarkers compared to conventional methods, yet they can lack physical insights into diagnosis. eXplainable Artificial Intelligence (XAI) is capable of providing deeper insights into the decision-making of complex ML algorithms increasing their applicability. We aim to introduce best practice for combining ML and XAI techniques for biomarker validation tasks.

Methods:

We focused on classification tasks and a game theoretic approach based on Shapley values to build and evaluate models and visualise results. We described the workflow and apply the pipeline in a case study using the CDAS PLCO Ovarian Biomarkers dataset to demonstrate the potential for accuracy and utility.

Results:

The case study results demonstrate the efficacy of the ML pipeline, its consistency, and advantages compared to conventional statistical approaches.

Conclusion:

The resulting guidelines provide a general framework for practical application of XAI in medical research that can inform clinicians and validate and explain cancer biomarkers.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-03 at 21:49